慢性HBV感染相关性肝癌发生的突变基因研究

摘要/Abstract

摘要： 最近与肿瘤发展相关的病毒基因突变已成为研究的主要焦点,慢性乙型肝炎病毒感染(HBV)仍然是肝细胞癌(HCC)最常见的危险因素。preS/S突变体被认为是HCC的“前体病变”,可诱导蛋白相关反应和内质网应激依赖及不依赖途径,它与HBx蛋白在HBV感染相关肝癌发生中起关键作用。还有HBV入胞转运体、DNA转录及miRNA也证明与肝癌进展相关。除了HBV和AFB1暴露外,宿主因素可能在HCC的发生中也发挥作用。然而,HBV感染促进HCC发展的分子机制尚不完全清楚。本文探讨了HBV相关性肝癌发生的突变基因,为肝癌的发生、发展及预测提供了思路。

关键词: 慢性HBV感染, 肝癌, preS/S, HBV x基因, 突变基因

何倩玉, 李俊峰, 毛小荣. 慢性HBV感染相关性肝癌发生的突变基因研究[J]. 肝脏, 2021, 26(7): 811-814.

参考文献

[1] Liu Z,Dai X,Wang T,et al.Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells.Cancer Lett,2017,400:149-160.
[2] Lee SA,Lee SY,Choi YM,et al.Sex disparity in viral load,inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region.World J Gastroenterol,2018,24:1084-1092.
[3] Wang H,Wang AH,Gressner OA,et al.Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China.Clin Exp Med,2015,15:483-491.
[4] Li H,Jia J,Wang M,et al.F221Y mutation in hepatitis B virus reverse transcriptase is associated with hepatocellular carcinoma prognosis following liver resection.Mol Med Rep,2017,15:3292-3300.
[5] Musa J,Li J,Grünewald TG.Hepatitis B virus large surface protein is priming for hepatocellular carcinoma development via induction of cytokinesis failure.J Pathol,2019,247:6-8.
[6] Yen CJ,Ai YL,Tsai HW,et al.Hepatitis B virus surface gene pre-S(2) mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection.Hepatology,2018,68:815-826.
[7] Song J,Zhang X,Ge Q,et al.CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells.J Cell Biochem,2018,119:8419-8431.
[8] Luan F,Liu B,Zhang J,et al.Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma.Pathol Res Pract,2017,213:1037-1042.
[9] Zhang X,Gao L,Liang X,et al.HBV preS2 transactivates FOXP3 expression in malignant hepatocytes.Liver Int,2015,35:1087-1094.
[10] 刘芬,周璇,季惠惠,等.三磷酸腺苷酶家族蛋白2在不同病变肝组织中的表达意义及临床应用探讨.中华肝脏病杂志,2017,25:339-343.
[11] Kawai-Kitahata F,Asahina Y,Tanaka S,et al.Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.J Gastroenterol,2016,51:473-486.
[12] Deng X,Zhao XF,Liang XQ,et al.Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.Biomed Pharmacother,2017,90:100-108.
[13] Lee D,Lyu H,Chung YH,et al.Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma.World J Gastroenterol,2016,22:5393-5399.
[14] Gong SJ,Feng XJ,Song WH,et al.Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.Cancer Biol Ther,2016,17:151-162.
[15] Tian JH,Liu WD,Zhang ZY,et al.Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2.J Viral Hepat,2019,26:496-505.
[16] Chen QY,Hu YL,Wang XY,et al.Locus 5p13.1 may be associated with the selection of cancer-related HBV core promoter mutations.Int J Med Sci,2019,16:990-997.
[17] Zhang J,Liu L,Lin Z,et al.SNP-SNP and SNP-environment interactions of potentially functional HOTAIR SNPs modify the risk of hepatocellular carcinoma.Mol Carcinog,2019,58:633-642.
[18] Hu HH,Liu J,Lin YL,et al.The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.Gut,2016,65:1514-1521.
[19] Shimizu T,Aoki T,Mori S,et al.Tumor DNA-dependent protein kinase catalytic subunit expression is associated with hepatitis B surface antigen status and tumor progression in patients with hepatocellular carcinoma.Sci Rep,2018,8:15019.
[20] Sunami Y,Ringelhan M,Kokai E,et al.Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response.Hepatology,2016,63:1592-1607.
[21] Deng M,Hou J,Hu J,et al.Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma.Cancer Lett,2016,383:62-72.
[22] Qiu D,Chen J,Liu J,et al.Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues.Exp Biol Med (Maywood),2017,242:939-944.
[23] 徐晓宏,高守宝,王玥,等.miRNA表达与免疫细胞因子相关性在原发性肝癌早期诊断和预后中的作用.中国免疫学杂志,2018,34:104-108.
[24] Liu Z,Li G,Gou Y,et al.JS-K,a nitric oxide prodrug,induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.Biomed Pharmacother,2017,92:989-997.
[25] Cheng S,Zhang B,Du JY,et al.Hepatitis B Surface Antigen Promotes the Invasion of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells by Upregulation of Toll-Like Receptor 2.Viral Immunol,2017,30:232-239.
[26] Jing X,Tian Z,Gao P,et al.HBsAg/β2GPI activates the NF?κB pathway via the TLR4/MyD88/IκBα axis in hepatocellular carcinoma.Oncol Rep,2018,40:1035-1045.
[27] Zhang R,Real CI,Liu C,et al.Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro.Int J Cancer,2017,141:354-363.
[28] Zhang X,Lv L,Ouyang X,et al.Association of TIP30 expression and prognosis of hepatocellular carcinoma in patients with HBV infection.Cancer Med,2016,5:2180-2189.
[29] Liu F,Li F,Luo L,et al.Genetic variants in cell death pathway genes and HBV-related hepatocellular carcinoma among a Chinese Han population.Apoptosis,2017,22:1035-1047.
[30] Wang ML,Wu DB,Tao YC,et al.The truncated mutant HBsAg expression increases the tumorigenesis of hepatitis B virus by regulating TGF-β/Smad signaling pathway.Virol J,2018,15:61.
[31] Park ER,Kim SB,Lee JS,et al.The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma.Cancer Med,2017,6:749-760.
[32] Liu Y,Hu C,Zhu WB,et al.Association of Low Zinc Finger Antiviral Protein Expression with Progression and Poor Survival of Patients with Hepatocellular Carcinoma.Cell Physiol Biochem,2018,49:1007-1018.